Table 1.
The characteristics of patients who received lusutrombopag
| All | Group A | Group B | p-value | |
|---|---|---|---|---|
| n | 31 | 23 (74.2%) | 8 (25.8%) | |
| Male/female | 21/10 | 13/10 | 8/0 | 0.0226 |
| Age (years) | 64.7 ± 8.8 | 64.8 ± 9.4 | 64.3 ± 6.9 | 0.6838 |
| Lusutrombopag 5/7 days | 3/28 | 3/20 | 0/8 | 0.2712 |
| History of platelet transfusion | 15/31(48%) | 10/23(43%) | 5/8(63%) | 0.3663 |
| HCV/HBV/NASH/ALC/others | 15/2/3/8/3 | 11/2/2/5/3 | 4/0/1/3/0 | |
| Child–Pugh A/B | 17/14 | 12/11 | 5/3 | 0.6206 |
| Child–Pugh score | 6.7 ± 1.3 | 6.7 ± 1.3 | 6.6 ± 1.5 | 0.7443 |
| ALBI | − 2.06 ± 0.62 | − 1.95 ± 0.60 | − 2.39 ± 0.54 | 0.0947 |
| FIB-4 | 13.24 ± 4.55 | 13.21 ± 5.02 | 13.33 ± 2.80 | 0.8923 |
| M2BPGi (COI) | 10.03 ± 5.28 | 10.49 ± 5.62 | 8.28 ± 3.13 | 0.3373 |
| TACE/RFA/EVL/EIS/others | 14/7/4/1/5 | 11/6/2/0/4 | 3/1/2/1/1 | |
| Period until the procedure (day) | 12.3 ± 1.9 | 12.3 ± 1.8 | 12.4 ± 2.2 | 0.8728 |
| Platelet count (× 104/µL) < 3.5/3.5–4.5/4.5 < | 9/13/9 | 4/10/9 | 5/3/0 | |
| Baseline platelet count (× 104/µL) | 3.9 ± 0.7 | 4.2 ± 0.6 | 3.1 ± 0.6 | 0.0010 |
| Platelet increase > 2 × 104/µL | 22 (71%) | 20 (87%) | 2 (25%) | 0.000802 |
| Splenic volume (mL) | 694 ± 321 | 615 ± 280 | 922 ± 322 | 0.0254 |
HCV hepatitis C virus, HBV hepatitis B virus, NASH non-alcoholic steatohepatitis, ALC alcohol, ALBI albumin–bilirubin, FIB-4 fibrosis-4, M2BPGi mac2 binding protein glucosylation isomer, TACE transcatheter arterial chemoembolization, RFA radiofrequency ablation, EVL endoscopic variceal ligation, EIS endoscopic injection sclerotherapy